Amgen stock: buy or sell?
Updated on:
November 19th, 2019
5
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology\u002Fhematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience.
Should I buy Amgen stock?
Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to choose your own trading strategy that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.These 2 buy setups are elegible for Amgen stock now:
| Buy setup | Elegible |
|---|---|
| New all-time high | Yes |
| New 52 week high | Yes |
| Price crossing up 200d MA | No |
| 100d MA crossing up 200d MA | No |
Is Amgen stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.
At Stocks2.com, we detected 15 ratings published for AMGN stock in the last month.| Date | Analyst / Broker | Previous rating | Current rating |
| 2019-9-5 | Cantor Fitzgerald | n/a | Neutral |
| 2019-9-29 | Mizuho | n/a | Hold |
| 2019-8-30 | William Blair | n/a | Hold |
| 2019-8-29 | JPMorgan Chase & Co. | n/a | Neutral |
| 2019-8-27 | Wells Fargo & Co | n/a | Market Perform |
| 2019-8-27 | Royal Bank of Canada | n/a | Sector Perform |
| 2019-8-27 | JPMorgan Chase & Co. | n/a | Hold |
| 2019-8-27 | BMO Capital Markets | n/a | Outperform |
| 2019-8-21 | Royal Bank of Canada | n/a | Sector Perform |
| 2019-8-19 | Mizuho | Buy | Neutral |
| 2019-8-16 | Credit Suisse Group | n/a | Outperform |
| 2019-8-13 | Oppenheimer | n/a | Outperform |
| 2019-8-12 | Wells Fargo & Co | Market Perform | Positive |
| 2019-7-15 | Morgan Stanley | n/a | Overweight |
| 2019-7-1 | Mizuho | n/a | Buy |
Amgen stock analysis
Daily outlook
After climbing to all-time highs several times in past weeks, Amgen jumped 1.74% to $224.50.
Amgen closed today at $224.50 after topping to a new all time high ($224.68) and jumped a fine 1.74%. Since SMA100d and SMA200d crossed up on October, AMGN price climbed $32.27 per share (16.79%). On August AMGN price bounced up over the SMA of 200 days demonstrating to be a significant support for this stock. AMGN shows a strong short term uptrend with several rising tops and rising bottoms. Since its last bottom on Thursday, AMGN climbed unceasignly breaking out to new all time highs.
Weekly outlook
Amgen stepped up 1.65% this week and peaked a new all time high at $224.68. With this, it's been 5 climbing weeks in a row, soaring a 11.59%. Late October AMGN rocketed an amazing 6.84% in just one week.
AMGN shows a strong mid-term uptrend with several rising tops and rising bottoms. Since its last bottom late September, AMGN climbed unceasignly breaking out to new all time highs. Since SMA20d and SMA40w crossed up late September, AMGN price climbed $28.86 per share (14.75%). Late July AMGN price bounced up over the SMA of 40 weeks that acted as support stopping new slides.
Amgen stock price history
Amgen stock went public on June 17th, 1983 with a price of $0.001. Since then, AMGN stock grew a inf%, with an average of inf% per year. If you had invested $1,000 in Amgen stock in 1983, it would worth $inf today.
1: Adjusted price after possible price splits or reverse-splits.
Amgen stock historical price chart
AMGN stock reached all-time highs today with a price of $224.68.
Amgen stock price target is $214.00
How much a stock will be priced tomorrow or next week is quite unpredictable However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. We found 13 price forecasts for Amgen stock posted in the last 30 days:| Date | Analyst / Broker | Action | Previous target | Current target | Diff |
| 2019-9-5 | Cantor Fitzgerald | Reiterates | $221.00 | $230.00 | 4.1% |
| 2019-9-29 | Mizuho | Reiterates | n/a | $212.00 | - |
| 2019-8-29 | JPMorgan Chase & Co. | Raises Target | $191.00 | $198.00 | 3.7% |
| 2019-8-27 | Wells Fargo & Co | Reiterates | $202.00 | $220.00 | 8.9% |
| 2019-8-27 | Royal Bank of Canada | Raises Target | $192.00 | $206.00 | 7.3% |
| 2019-8-27 | BMO Capital Markets | Raises Target | $230.00 | $240.00 | 4.3% |
| 2019-8-21 | Royal Bank of Canada | Raises Target | n/a | $192.00 | - |
| 2019-8-19 | Mizuho | Downgrades | $208.00 | $212.00 | 1.9% |
| 2019-8-16 | Credit Suisse Group | Reiterates | $202.00 | $225.00 | 11.4% |
| 2019-8-13 | Oppenheimer | Raises Target | $210.00 | $230.00 | 9.5% |
| 2019-8-12 | Wells Fargo & Co | Reiterates | $197.00 | $202.00 | 2.5% |
| 2019-7-15 | Morgan Stanley | Lowers Target | $211.00 | $207.00 | -1.9% |
| 2019-7-1 | Mizuho | Reiterates | n/a | $208.00 | - |
| (in average) | $206.40 | $214.00 | 4.0% |
Financials and fundamental analysis
Earnings date and Earnings per Share
Since last April, when Amgen posted its last earnings report, it . Unfortunately, reported EPS is not yet available in our database.| Quarter | Reporting date | Estimated EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| 2017-Q2 | - | n/a | 2.91 | n/a |
| 2017-Q3 | 2017-10-25 | 3.11 | 3.27 | 5.1% |
| 2017-Q4 | 2018-02-01 | 3.03 | 2.89 | -4.6% |
| 2018-Q1 | 2018-04-24 | 3.23 | 3.47 | 7.4% |
| 2018-Q2 | 2018-07-26 | 3.52 | 3.83 | 8.8% |
| 2018-Q3 | 2018-10-30 | 3.42 | 3.69 | 7.9% |
| 2018-Q4 | 2019-01-29 | 3.26 | 3.42 | 4.9% |
| 2019-Q1 | 2019-04-22 | 3.48 | n/a | n/a |
| 2019-Q2 | - | n/a | n/a | n/a |
| 2019-Q3 | - | n/a | n/a | n/a |
Annual financial results
In 2018, Amgen annual revenues inched a good 3.93% to $23,747.00 M USD from $22,849.00 marked in 2017. When comparing 2018 vs 2017, slightly better, profit margin (that is, the net income divided by revenues) skyrocketed a 26.69% to 35.35%. To have an updated view of the financial situation of Amgen, we have calculated the trailing twelve month (TTM) sales and income figures. TTM values are the sum of the last 4 quarters and aproximate to an annual fiscal report ending in 2019-Q1 that can be compared to 2018 fiscal year results. Annual Amgen TTM sales up to March 2019 were $23,750.00 and earnings were $8,075.00 million USD. When comparing this TTM figures with the last reported annuality, we can review Amgen business evolution since December 2018: Annual sales up to March, compared to lastest yearly report, remained stable a tight 0.01%. Similarly, profit margin (net income/sales) depreciated at 35.35%.| Year | Sales | YoY | Income/(margin) | YoY |
|---|---|---|---|---|
| 2013 | $18,670 M | - | $5,080 M27.2% | - |
| 2014 | $20,063 M | 7.46% | $5,158 M25.7% | 1.54% |
| 2015 | $21,662 M | 7.97% | $6,939 M32.0% | 34.53% |
| 2016 | $22,991 M | 6.14% | $7,722 M33.6% | 11.28% |
| 2017 | $22,849 M | -0.62% | $1,979 M8.7% | -74.37% |
| 2018 | $23,747 M | 3.93% | $8,394 M35.3% | 324.15% |
| TTM | $23,750 M | 0.01% | $8,075 M34.0% | -3.80% |
Quarterly financial results
Amgen posted $5,557.00 million in sales for 2019-Q1, a -10.80% less compared to previous quarter. Reported quarter earnings marked $1,992.00 million with a profit margin of 35.85%. Profit margin raised a 4.90% compared to previous quarter when profit margin was 30.95%. When comparing turnover to same quarter last year, Amgen sales marked a neutral movement and stayed steady a 0.05%.| Quarter | Sales1 | QoQ2 | Income1/(margin) | QoQ2 |
|---|---|---|---|---|
| 2017-Q2 | $5,780 M | - | $2,150 M37.2% | - |
| 2017-Q3 | $5,780 M | 0.00% | $2,020 M34.9% | -6.05% |
| 2017-Q4 | $5,802 M | 0.38% | $-4,264 M-73.5% | -311.09% |
| 2018-Q1 | $5,554 M | -4.27% | $2,311 M41.6% | -154.20% |
| 2018-Q2 | $6,059 M | 9.09% | $2,296 M37.9% | -0.65% |
| 2018-Q3 | $5,904 M | -2.56% | $1,859 M31.5% | -19.03% |
| 2018-Q4 | $6,230 M | 5.52% | $1,928 M30.9% | 3.71% |
| 2019-Q1 | $5,557 M | -10.80% | $1,992 M35.8% | 3.32% |
Amgen ownership
When you are planning to invest in shares of a company, it's worth to review its ownership structure.Amgen shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.21% of all shares.
Bearish positions for AMGN stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Amgen:
| AMGN | ABBV | ALXN | BIIB | BMY | |
|---|---|---|---|---|---|
| Market cap | $133.4 B | $131.3 B | $24.2 B | $51.0 B | $94.0 B |
| Total shares | 594.2 M | 1,480.0 M | 224.2 M | 180.4 M | 1,630.0 M |
| Float shares | 592.9 M | 1,480.0 M | 220.7 M | 180.0 M | 1,630.0 M |
| - Institutional holdings (%) | 81.9% | 71.9% | 96.8% | 93.4% | 75.0% |
| - Insider holdings (%) | 0.2% | 0.1% | 0.3% | 0.5% | 0.1% |
| Shares in short selling | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Amgen summary
| Tuesday, November 19th, 2019 | |
|---|---|
| Open | $221.24 |
| Close | $224.50 |
| Day range | $220.70 - $224.68 |
| Previous close | $220.67 |
| Session gain | 1.74% |
| Average true range | $4.18 |
| 50d mov avg | $203.16 |
| 100d mov avg | $196.02 |
| 200d mov avg | $187.34 |
| Daily pattern | lb03c |
| Weekly pattern | lb03c |
Amgen performance
To better understand Amgen performance you must compare its gains with other related stocks in same sector or industry. We picked AbbVie, Alexion Pharmaceuticals, Biogen, Bristol-Myers Squibb, Celgene, Gilead Sciences, GlaxoSmithKline, and Pfizer as the bechmarking frame for Amgen stock.| Stock | 3m | 6m | 12m |
|---|---|---|---|
| AMGNAmgen | 13.52% | 32.88% | 20.12% |
| ABBVAbbVie | 38.47% | 15.85% | 11.09% |
| ALXNAlexion Pharmaceu... | -6.38% | -15.01% | -8.58% |
| BIIBBiogen | 25.14% | 24.47% | -11.70% |
| BMYBristol-Myers Squ... | 24.81% | 25.30% | 12.66% |
| CELGCelgene | 16.31% | 14.78% | 64.02% |
| GILDGilead Sciences | 3.81% | -2.07% | 0.17% |
| GSKGlaxoSmithKline | 9.20% | 13.26% | 14.93% |
| JNJ | 6.35% | -2.17% | -2.59% |
| PFEPfizer | 9.44% | -9.57% | -10.53% |
Amgen competitors
One check before investing in any stock is to have a look a list of its competitors, in this case for Amgen. We chose 9 companies as Amgen competitors as they are in the same industry or have similar market objectives.- AbbVie (ABBV)
- Alexion Pharmaceuticals (ALXN)
- Biogen (BIIB)
- Bristol-Myers Squibb (BMY)
- Celgene (CELG)
- Gilead Sciences (GILD)
- GlaxoSmithKline (GSK)
- (JNJ)
- Pfizer (PFE)
Latest Amgen stock news
- Seeking AlphaMirati's Stock Gaps Higher On Amgen's Data, Opens Up Massive OpportunityJune 6, 2019
- Seeking AlphaAmgen Breaches Hurdle For Decades Of Research To Bring A New Drug To RealityJune 6, 2019
- InvestorPlaceAmgen Earnings: AMGN Stock Dips Slightly Despite Q1 EPS, Sales BeatApril 30, 2019
- Seeking AlphaAmgen Evenity Approval Just Makes It A HoldApril 18, 2019
- InvestorPlace3 Big Stock Charts for Thursday: Citrix Systems, Goldman Sachs Group and AmgenApril 18, 2019